• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Dateline Resources Ltd
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

10.95 +0.64 (+6.21%)
Delayed Quote Updated: 4:00 PM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,343,518
Open 10.34
Bid (Size) 10.98 (500)
Ask (Size) 11.00 (100)
Prev. Close 10.31
Today's Range 10.34 - 11.41
52wk Range 5.250 - 11.41
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
October 15, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 02, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire

Performance

52-Week Range 4.1% below 52-week high
10.95
5.2552W Low 11.4152W High
1 Week 4.1% below 1-week high
9.731W Low 11.411W High

Xeris Biopharma Holdings, Inc. - Common Stock (XERS) traded between $5.25 and $11.41 over the past 52 weeks and last traded at $10.95, 4.1% below its 52-week high. Over the past week it ranged between $9.73 and $11.41.

Past 12 Months
+7.4%
+24.4%
+27.3%
+75.2%
+49.0%
+17.2%
1W +$0.75
1M +$2.15
3M +$2.35
6M +$4.70
YTD +$3.60
1Y +$1.61

XERS was +17.2% over the past year, +75.2% over six months, +49.0% year to date, +7.4% in the last week.

12 Months vs Market
XERS
+17.2%
DIA
+11.1%
SPY
+14.2%
QQQ
+17.5%
IWM
+9.3%

Over the past 12 months XERS returned +17.2% versus DIA (Dow) +11.1%, SPY (S&P 500) +14.2%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +9.3%.

Volume & Liquidity 1.90× 3-mo avg
Today 4,343,518 3-mo avg 2.3M
1W
2.6M
1M
3.4M
3M
2.3M
6M
2.1M
YTD
2.0M
1Y
2.1M

XERS most recently traded 4,343,518 shares against a 3-month average daily volume of 2.3M.

More News

Read More
News headline image
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
September 09, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Details for XP-8121 Program Overview Webinar
August 26, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma (NASDAQ:XERS) Achieves First Profit, Beats Q1 Estimates with 95% Recorlev Surge ↗
May 07, 2026
Via Chartmill
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges on Strong Q4 Earnings and Robust 2026 Outlook ↗
March 02, 2026
Via Chartmill
News headline image
Xeris (XERS) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings Intellectual Property Retirement
News headline image
Xeris Biopharma Q2 Earnings Call Highlights ↗
August 07, 2026
Via MarketBeat
Topics Earnings Retirement
News headline image
Xeris Biopharma Reports Second Quarter 2026 Financial Results
August 06, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 02, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Updates to Its Board of Directors
June 30, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
June 11, 2026
From Xeris Pharmaceuticals, Inc.
Via Business Wire
News headline image
Xeris Biopharma Announces Private Exchange of Convertible Notes
June 11, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Q1 Earnings Call Highlights ↗
May 09, 2026
Via MarketBeat
Topics Earnings
News headline image
Xeris (XERS) Q1 2026 Earnings Call Transcript ↗
May 07, 2026
Via The Motley Fool
Topics Earnings
News headline image
Xeris Biopharma Reports First Quarter 2026 Financial Results
May 07, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
April 23, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript ↗
March 02, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
March 02, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
February 26, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
February 17, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
January 08, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 02, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire

Frequently Asked Questions

Is Xeris Biopharma Holdings, Inc. - Common Stock publicly traded?
Yes, Xeris Biopharma Holdings, Inc. - Common Stock is publicly traded.
What exchange does Xeris Biopharma Holdings, Inc. - Common Stock trade on?
Xeris Biopharma Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock?
The ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock is XERS on the Nasdaq Stock Market
What is the current price of Xeris Biopharma Holdings, Inc. - Common Stock?
The current price of Xeris Biopharma Holdings, Inc. - Common Stock is 10.95
When was Xeris Biopharma Holdings, Inc. - Common Stock last traded?
The last trade of Xeris Biopharma Holdings, Inc. - Common Stock was at 10/19/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap